演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

末梢ルートでの婦人科がん化学療法の NK1受容体阻害剤は アプレピタントが望ましい

演題番号 : P30-5

[筆頭演者]
演者)松元 隆:1 
[共同演者]
宇佐美 知香:1、森 奈月:2、安岡 稔晃:1、井上 翔太:1、今井 統:1、吉田 文香:1、宮上 眸:1、横山 真紀:1、内倉 友香:1、高木 香津子:1、松原 裕子:1、藤岡 徹:1、松原 圭一:1、杉山 隆:1

1:愛媛大学・産科婦人科、2:愛媛大学附属病院・外来化学療法室

 

[Background] Recently, guidelines for antiemesis of ASCO, NCCN and MASCC/ESMO were updated, and adult patients who are treated with carboplatin AUC >= 4 should be offered a three-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone. In November 2017, we started using fosaprepitant in gynecologic cancer patients treated with paclitaxel and carboplatin. We experienced the high incidence of injection site reaction in these patients.
[Methods] We analyzed injection site reaction in 32 patients administrated with fosaprepitant between November and December 2017 in our hospital. Adverse events were graded according to CTCAE ver. 4.0. In all patients, peripheral intravenous lines were used.
[Results] Median age of patients was 61 years old. Sites of primary tumor were 14 ovaries, 8 endometrium and 8 uterine cervix. The incidence of injection site reaction was 25% (8/32). Adverse events were graded as G2 in 7 patients (87.5%) and G1 in 1 patient (12.5%). In 2 patients, the administration of fosaprepitant was discontinued. In a patient, the intravenous route was reestablished, and extravasation of anticancerous agents was occurred. Based on experience of these adverse events, we decided to change fosaprepitant to (oral) aprepitant as an NK1 receptor antagonist from January 2018.
[Conclusion] Because this high incidence of injection site reaction in patients administrated with fosaprepitant cannot be tolerated clinically, it seemed preferable to use (oral) aprepitant in patients using peripheral intravenous line.

キーワード

臓器別:その他

手法別:支持療法

前へ戻る